Back to SRPT Stock Lookup
Pages: 1 2 »» Last Page

SRPT – Analyst Ratings

Apr 7, 2014 12:03 PM Needham & Company Confirms Sarepta Therapeutic (SRPT) Pulls From Conference; Likely Due to FDA Meeting
Jan 27, 2014 06:56 AM JMP Securities Downgrades Sarepta Therapeutic (SRPT) to Market Perform
Jan 21, 2014 06:55 AM Needham & Company Upgrades Sarepta Therapeutic (SRPT) to Buy, $36 PT
Jan 6, 2014 09:09 AM UPDATE: Citi Downgrades Sarepta Therapeutic (SRPT) to Sell
Dec 23, 2013 06:42 AM Piper Jaffray Upgrades Sarepta Therapeutic (SRPT) to Neutral
Dec 6, 2013 07:44 AM Canaccord Genuity Downgrades Sarepta Therapeutic (SRPT) to Hold
Nov 12, 2013 03:54 PM Deutsche Bank Cuts Sarepta Therapeutic (SRPT) to Hold, PT $17
Nov 12, 2013 02:45 PM FBR Capital Slashes Sarepta (SRPT) Price Target, But Remains 49% Above Current Levels
Nov 12, 2013 02:22 PM Sarepta (SRPT) Target Cut to $45 at Wedbush, Analyst Expects Larger Eteplirsen Trial
Nov 12, 2013 12:46 PM Needham & Company Downgrades Sarepta Therapeutic (SRPT) to Hold
Nov 12, 2013 09:25 AM Sarepta (SRPT) Eteplirsen Delay Impacts DCF by $10/sh Each Year - Deutsche Bank
Nov 12, 2013 08:11 AM Piper Jaffray Downgrades Sarepta Therapeutic (SRPT) to Underweight
Oct 30, 2013 08:12 AM FBR Capital Starts Sarepta Therapeutic (SRPT) at Market Perform
Oct 7, 2013 10:38 AM Sarepta (SRPT) Fair Value as High as $213 - Deutsche Bank
Oct 3, 2013 08:59 AM Baird Maintains Buy on Sarepta Therapeutic (SRPT)
Sep 23, 2013 12:42 PM PTC Therapeutics (PTCT) Reiterated Buy at Wedbush
Sep 23, 2013 07:59 AM Drisapersen Failure Net Positive for Sarepta's (SRPT) Eteplirsen - Needham & Company
Sep 20, 2013 11:47 AM Piper Jaffray Upgrades Sarepta Therapeutic (SRPT) to Overweight
Sep 20, 2013 11:08 AM Deutsche Bank Upgrades Sarepta Therapeutic (SRPT) to Buy
Sep 20, 2013 10:12 AM Drisapersen Read-Through for Sarepta's (SRPT) Eteplirsen - Deutsche Bank
Sep 5, 2013 04:26 PM Stifel Nicolaus Starts Sarepta Therapeutic (SRPT) at Buy
Aug 27, 2013 06:45 AM Citi Starts Sarepta Therapeutic (SRPT) at Neutral
Aug 19, 2013 03:26 PM Sarepta (SRPT) Dystrophin Quantification Analyses Intact Despite Photo Error
Jul 24, 2013 10:13 AM Burrill Downgrades Sarepta Therapeutic (SRPT) to Market Perform
Jul 24, 2013 09:56 AM Deutsche Bank Downgrades Sarepta Therapeutic (SRPT) to Hold
Jul 24, 2013 09:15 AM UPDATE: Piper Jaffray Downgrades Sarepta Therapeutic (SRPT) to Neutral
Jun 27, 2013 12:29 PM Sarepta's (SRPT) Eteplirsen Can Still Get Breakthrough for DMD, Deutsche Bank Says (GSK)
Jun 26, 2013 12:24 PM Sarepta (SRPT) Management Firm on Eteplirsen Guidance, Robert Baird Says
Jun 26, 2013 10:50 AM Risk Seen for Breakthrough Designation of Sarepta (SRPT) Eteplirsen - Deutsche Bank
May 30, 2013 03:53 PM Wedbush Says Sarepta (SRPT) May File for Accelerated Approval in H1 2014
May 28, 2013 03:58 PM Sarepta Therapeutic's (SRPT) Eteplirsen Could Have Safety Advantage
May 13, 2013 12:28 PM Big Potential, Yet Hurdles Remain for Sarepta Therapeutic (SRPT) - Burrill
Apr 22, 2013 08:10 AM Needham & Company Starts Sarepta Therapeutic (SRPT) at Buy
Apr 16, 2013 07:08 AM Leerink Swann Downgrades Sarepta Therapeutic (SRPT) to Market Perform on Lack of FDA Clarity
Apr 16, 2013 07:05 AM Janney Montgomery Scott Downgrades Sarepta Therapeutic (SRPT) to Neutral
Apr 15, 2013 01:06 PM Wedbush Sees Sarepta Therapeutics (SRPT) Filing for Accelerated Approval of Eteplirsen
Apr 9, 2013 05:34 PM Study Helps Validates Sarepta Therapeutic's (SRPT) Technology
Apr 9, 2013 07:07 AM Canaccord Genuity Starts Sarepta Therapeutic (SRPT) at Buy
Apr 3, 2013 04:29 PM Baird Starts Sarepta Therapeutic (SRPT) at Outperform
Mar 20, 2013 07:49 AM William Blair Starts Sarepta Therapeutic (SRPT) at Outperform
Mar 19, 2013 08:02 AM Deutsche Bank Starts Sarepta Therapeutic (SRPT) at Buy; Could Be Worth Up to $71/Sh
Mar 5, 2013 06:56 AM Leerink Swann Starts Sarepta Therapeutic (SRPT) at Outperform, $45 PT
Jan 25, 2013 08:08 AM Cowen Starts Sarepta Therapeutic (SRPT) at Outperform
Nov 27, 2012 09:14 AM Dawson James Starts Sarepta Therapeutic (SRPT) at Market Outperform
Nov 26, 2012 02:54 PM Burrill Starts Sarepta (SRPT) at Market Outperform; Sees Plenty of Upside in DMD Space
Nov 26, 2012 09:56 AM Burrill Starts Sarepta Therapeutic (SRPT) at Market Outperform
Nov 21, 2012 09:18 AM Sarepta Therapeutics (SRPT) Jumps on Bullish Comments
Oct 4, 2012 03:50 PM Wedbush Lifts Target on Sarepta Therapeutic (SRPT) to $70, Drug Could Sell for $300-$400K/year
Oct 3, 2012 07:58 AM Sarepta Therapeutic (SRPT) Could Be Worth $83-$139/Sh - Analyst
Sep 12, 2012 09:36 AM WBB Securities Downgrades Sarepta Therapeutic (SRPT) to Sell
Pages: 1 2 »» Last Page

Back to SRPT Stock Lookup